LAS VEGAS--(BUSINESS WIRE)--Sept. 6, 2006--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced that it has engaged The Bruckner Group (BGI) to help develop the value proposition for its drug candidates for the treatment of cardiovascular diseases formulated with Cardio Vascu-Grow(TM). The Bruckner Group is the leading expert in developing strategies for pharmaceutical and biotechnology companies to maximize, define, prove, and leverage the healthcare value of their therapeutics. BGI will work with CardioVascular BioTherapeutics to economically evaluate Cardio Vascu-Grow(TM) in order to secure the broadest possible payer coverage and clinical utilization.
